Please assess the completion status of the following clinical trial:

Trial Title: Safety of Nasal Influenza Immunisation in Egg Allergic Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 - 17 years old~* Physician-diagnosis of egg allergy~Exclusion Criteria:~* Contraindicated as acutely unwell or current unstable asthma~* Use of asthma reliever medication in last 72 hours~* Recent administration of a medication containing antihistamine within the last 4 days~* Current oral steroid for asthma exacerbation or course completed within last 2 weeks~* Contraindications to ingredient in LAIV (notwithstanding allergy to egg protein)~* Previous allergic reaction to an influenza vaccine~* Children and adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids.~* Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Egg allergic children (Type: None): Administration of Live attenuated influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).